Literature DB >> 27931796

The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.

Michael W Weiner1, Dallas P Veitch2, Paul S Aisen3, Laurel A Beckett4, Nigel J Cairns5, Robert C Green6, Danielle Harvey4, Clifford R Jack7, William Jagust8, John C Morris3, Ronald C Petersen9, Jennifer Salazar3, Andrew J Saykin10, Leslie M Shaw11, Arthur W Toga12, John Q Trojanowski13.   

Abstract

INTRODUCTION: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study.
METHODS: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition.
RESULTS: Multimodal analyses will provide insight into AD pathophysiology and disease progression. DISCUSSION: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.
Copyright © 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid phenotyping; Brain Health Registry; Centiloid method; Clinical trial biomarkers; Functional connectivity; Tau imaging

Mesh:

Substances:

Year:  2016        PMID: 27931796      PMCID: PMC5536850          DOI: 10.1016/j.jalz.2016.10.006

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  81 in total

1.  Intraindividual cognitive decline using a brief computerized cognitive screening test.

Authors:  David G Darby; Robert H Pietrzak; Julia Fredrickson; Michael Woodward; Lynette Moore; Amy Fredrickson; Jack Sach; Paul Maruff
Journal:  Alzheimers Dement       Date:  2012       Impact factor: 21.566

2.  Perspective on the Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Zaven S Khachaturian
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

3.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

4.  Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.

Authors:  Paul S Aisen; Bruno Vellas; Harald Hampel
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

5.  Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.

Authors:  Charles Bernick; Jeffrey Cummings; Rema Raman; Xiaoying Sun; Paul Aisen
Journal:  Arch Neurol       Date:  2012-07

6.  Gene-based GWAS and biological pathway analysis of the resilience of executive functioning.

Authors:  Shubhabrata Mukherjee; Sungeun Kim; Vijay K Ramanan; Laura E Gibbons; Kwangsik Nho; M Maria Glymour; Nilüfer Ertekin-Taner; Thomas J Montine; Andrew J Saykin; Paul K Crane
Journal:  Brain Imaging Behav       Date:  2014-03       Impact factor: 3.978

Review 7.  The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

Authors:  Ju-Hee Kang; Magdalena Korecka; Michal J Figurski; Jon B Toledo; Kaj Blennow; Henrik Zetterberg; Teresa Waligorska; Magdalena Brylska; Leona Fields; Nirali Shah; Holly Soares; Robert A Dean; Hugo Vanderstichele; Ronald C Petersen; Paul S Aisen; Andrew J Saykin; Michael W Weiner; John Q Trojanowski; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

Review 8.  Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Authors:  Andrew J Saykin; Li Shen; Xiaohui Yao; Sungeun Kim; Kwangsik Nho; Shannon L Risacher; Vijay K Ramanan; Tatiana M Foroud; Kelley M Faber; Nadeem Sarwar; Leanne M Munsie; Xiaolan Hu; Holly D Soares; Steven G Potkin; Paul M Thompson; John S K Kauwe; Rima Kaddurah-Daouk; Robert C Green; Arthur W Toga; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

9.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

Authors:  Eric R Siemers; Karen L Sundell; Christopher Carlson; Michael Case; Gopalan Sethuraman; Hong Liu-Seifert; Sherie A Dowsett; Michael J Pontecorvo; Robert A Dean; Ronald Demattos
Journal:  Alzheimers Dement       Date:  2015-08-01       Impact factor: 21.566

10.  Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.

Authors:  Tobias Bittner; Henrik Zetterberg; Charlotte E Teunissen; Richard E Ostlund; Michael Militello; Ulf Andreasson; Isabelle Hubeek; David Gibson; David C Chu; Udo Eichenlaub; Peter Heiss; Uwe Kobold; Andreas Leinenbach; Kairat Madin; Ekaterina Manuilova; Christina Rabe; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2015-11-10       Impact factor: 21.566

View more
  68 in total

1.  Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

Authors:  Adam M Staffaroni; Lynn Bajorek; Kaitlin B Casaletto; Yann Cobigo; Sheng-Yang M Goh; Amy Wolf; Hilary W Heuer; Fanny M Elahi; Peter A Ljubenkov; Reilly Dever; John Kornak; Brian Appleby; Jessica Bove; Yvette Bordelon; Patrick Brannelly; Danielle Brushaber; Christina Caso; Giovanni Coppola; Christina Dheel; Bradford C Dickerson; Susan Dickinson; Sophia Dominguez; Kimiko Domoto-Reilly; Kelly Faber; Jessica Ferrall; Julie A Fields; Ann Fishman; Jamie Fong; Tatiana Foroud; Leah K Forsberg; Ralitza Gavrilova; Debra Gearhart; Behnaz Ghazanfari; Nupur Ghoshal; Jill Goldman; Jonathan Graff-Radford; Neill Graff-Radford; Ian Grant; Murray Grossman; Dana Haley; Ging-Yuek Hsiung; Edward D Huey; David J Irwin; David T Jones; Lynne Jones; Kejal Kantarci; Anna Karydas; Daniel I Kaufer; Diana R Kerwin; David S Knopman; Ruth Kraft; Walter K Kremers; Walter A Kukull; Irene Litvan; Diane Lucente; Codrin Lungu; Ian R Mackenzie; Miranda Maldonado; Masood Manoochehri; Scott M McGinnis; Emily McKinley; Mario F Mendez; Bruce L Miller; Namita Multani; Chiadi Onyike; Jaya Padmanabhan; Alex Pantelyat; Rodney Pearlman; Len Petrucelli; Madeline Potter; Rosa Rademakers; Eliana Marisa Ramos; Katherine P Rankin; Katya Rascovsky; Erik D Roberson; Emily Rogalski; Pheth Sengdy; Leslie M Shaw; Jeremy Syrjanen; M Carmela Tartaglia; Nadine Tatton; Joanne Taylor; Arthur Toga; John Q Trojanowski; Sandra Weintraub; Ping Wang; Bonnie Wong; Zbigniew Wszolek; Adam L Boxer; Brad F Boeve; Joel H Kramer; Howard J Rosen
Journal:  Alzheimers Dement       Date:  2019-05-11       Impact factor: 21.566

Review 2.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

3.  A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data.

Authors:  Hongming Li; Mohamad Habes; David A Wolk; Yong Fan
Journal:  Alzheimers Dement       Date:  2019-06-11       Impact factor: 21.566

4.  Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Authors:  Ganesh M Babulal; Yakeel T Quiroz; Benedict C Albensi; Eider Arenaza-Urquijo; Arlene J Astell; Claudio Babiloni; Alex Bahar-Fuchs; Joanne Bell; Gene L Bowman; Adam M Brickman; Gaël Chételat; Carrie Ciro; Ann D Cohen; Peggye Dilworth-Anderson; Hiroko H Dodge; Simone Dreux; Steven Edland; Anna Esbensen; Lisbeth Evered; Michael Ewers; Keith N Fargo; Juan Fortea; Hector Gonzalez; Deborah R Gustafson; Elizabeth Head; James A Hendrix; Scott M Hofer; Leigh A Johnson; Roos Jutten; Kerry Kilborn; Krista L Lanctôt; Jennifer J Manly; Ralph N Martins; Michelle M Mielke; Martha Clare Morris; Melissa E Murray; Esther S Oh; Mario A Parra; Robert A Rissman; Catherine M Roe; Octavio A Santos; Nikolaos Scarmeas; Lon S Schneider; Nicole Schupf; Sietske Sikkes; Heather M Snyder; Hamid R Sohrabi; Yaakov Stern; Andre Strydom; Yi Tang; Graciela Muniz Terrera; Charlotte Teunissen; Debora Melo van Lent; Michael Weinborn; Linda Wesselman; Donna M Wilcock; Henrik Zetterberg; Sid E O'Bryant
Journal:  Alzheimers Dement       Date:  2018-12-13       Impact factor: 21.566

5.  Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD Study).

Authors:  Amanda N Szabo-Reed; Eric Vidoni; Ellen F Binder; Jeffrey Burns; C Munro Cullum; William P Gahan; Aditi Gupta; Linda S Hynan; Diana R Kerwin; Heidi Rossetti; Ann M Stowe; Wanpen Vongpatanasin; David C Zhu; Rong Zhang; Jeffrey N Keller
Journal:  Contemp Clin Trials       Date:  2019-03-01       Impact factor: 2.226

6.  Cognitive Performance in Parkinson's Disease in the Brain Health Registry.

Authors:  Brenna Cholerton; Michael W Weiner; Rachel L Nosheny; Kathleen L Poston; R Scott Mackin; Lu Tian; J Wesson Ashford; Thomas J Montine
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

7.  Perivascular space fluid contributes to diffusion tensor imaging changes in white matter.

Authors:  Farshid Sepehrband; Ryan P Cabeen; Jeiran Choupan; Giuseppe Barisano; Meng Law; Arthur W Toga
Journal:  Neuroimage       Date:  2019-04-30       Impact factor: 6.556

8.  Virtual Connectomic Datasets in Alzheimer's Disease and Aging Using Whole-Brain Network Dynamics Modelling.

Authors:  Lucas Arbabyazd; Kelly Shen; Zheng Wang; Martin Hofmann-Apitius; Petra Ritter; Anthony R McIntosh; Demian Battaglia; Viktor Jirsa
Journal:  eNeuro       Date:  2021-07-06

9.  Longitudinal Modeling of Functional Decline Associated with Pathologic Alzheimer's Disease in Older Persons without Cognitive Impairment.

Authors:  Dai Wang; Tim Schultz; Gerald P Novak; Susan Baker; David A Bennett; Vaibhav A Narayan
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Automated Multi-Atlas Segmentation of Hippocampal and Extrahippocampal Subregions in Alzheimer's Disease at 3T and 7T: What Atlas Composition Works Best?

Authors:  Long Xie; Russell T Shinohara; Ranjit Ittyerah; Hugo J Kuijf; John B Pluta; Kim Blom; Minke Kooistra; Yael D Reijmer; Huiberdina L Koek; Jaco J M Zwanenburg; Hongzhi Wang; Peter R Luijten; Mirjam I Geerlings; Sandhitsu R Das; Geert Jan Biessels; David A Wolk; Paul A Yushkevich; Laura E M Wisse
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.